News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
Ascendis Pharma A/S To Present At Three Upcoming Investor Conferences 9/4/2015
Hutchison China MediTech (Chi-Med) Release: Second Proof-Of-Concept Trial Of Fruquintinib Achieves Its Primary Endpoint 9/4/2015
Motif Bio plc, Release: FDA Grants Fast Track Designation For Iclaprim 9/3/2015
Axovant (AXON) To Present At Upcoming Investor Conferences 9/3/2015
Helsinn Group Signs Exclusive Agreement With Munipharma For The Distribution And Licence Of Anamorelin In Switzerland And Liechtenstein 9/3/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Xaracoll MATRIX-1 Phase III Study For The Treatment Of Postoperative Pain 9/2/2015
Bayer (BAY) Moves to Phase III Studies After Finerenone Cuts Deaths in Mid-Stage Trial 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Chiasma Reports Second Quarter 2015 Financial Results And Recent Business Highlights 9/1/2015
Janssen Pharmaceuticals, Inc. Release: New Global Real-World Data From Atrial Fibrillation Studies Confirm The Safety Profile Of XARELTO 9/1/2015
Ipsen (IPN.PA) Announces Publication In The Lancet Neurology Of The Results Of The Phase III Randomized Study (NCT01313299) Showing Efficacy And Safety Of Dysport (Abobotulinumtoxina) In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015
Resverlogix (RVX.TO) Presents New Data At The European Society of Cardiology Congress 2015 On RVX-208 'Apabetalone' A Selective BET Inhibitor 8/31/2015
NeuroVive Discontinues Ciclomulsion for Myocardial Infarction 8/31/2015
Telesta Receives FDA BLA Filing Notification Letter And Priority Review Designation For MCNA(1) 8/31/2015
Eisai Company (ESALY.PK) And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant 8/31/2015
PRANA Biotechnology (PRAN) Reports FY15 Financial Results 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook 8/27/2015
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
Macrocure (MCUR) Sinks as CureXcell Flunks Phase III Study 8/20/2015
VBL Therapeutics (VBLX) Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
Boehringer Ingelheim Release: CHMP Recommends Label Update For Giotrif With Addition Of Data Demonstrating Overall Survival Benefit For Patients With EGFR Mutation-Positive Lung Cancer 8/19/2015
LEO Pharma Release: New Study Investigating The Effect Of Low-Molecular-Weight Heparins On The Treatment Of Blood Clots In Cancer Patients 8/19/2015
Swedish Orphan Biovitrum Release: Results From B-YOND Study Reinforce Long-Term Clinical Profile Of Alprolix For The Treatment Of Haemophilia B 8/18/2015
Chiasma Announces FDA Acceptance For Filing Of New Drug Application For Octreotide Capsules In Acromegaly 8/17/2015
Mesoblast (MSB.AX) Reports 2015 Financial Year Results And Provides Update On Phase III Chronic Heart Failure Program 8/17/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
AEterna Zentaris (AEZS) Second Quarter Financial And Operating Results 8/14/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
CrystalGenomics Partners With Dong-A ST For Acelex Commercialization In Korea 8/13/2015
RedHill Biopharma Ltd. (RDHL) To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease 8/12/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015
Horizon Pharma (HZNP) Announces Record Second Quarter 2015 Financial Results 8/10/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
TiGenix Obtains FDA's Endorsement Through Special Protocol Assessment For Its Cx601 Phase III Registration Trial In The US 8/7/2015
Orexigen (OREX) Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical 8/6/2015
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015
Trimel Pharmaceuticals (TRL.TO) Announces Second Quarter 2015 Financial Results And Highlights 8/5/2015
Ipsen (IPN.PA)’s Partner, Lexicon Pharma (LXRX), Announces Positive Results From TELESTAR Phase 3 Study Showing That Telotristat Etiprate Is Effective In The Treatment Of Carcinoid Syndrome Caused By Neuroendocrine Tumors Not Adequately Controlled By Somatostatin 8/3/2015
Shionogi, Inc.'s Naldemedine Meets Endpoints In Phase III Study 8/3/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Cipher Pharma (DND.TO) Announces Successful Completion Of Second Phase III For Ozenoxacin 7/30/2015
Sanofi (SNY)'s Lixilan Hits Phase III Goal 7/29/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
As Biogen (BIIB), Eli Lilly (LLY) Fall Short, Roche (RHHBY) Intensifies Work on Two Alzheimer's Drugs 7/23/2015
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015
AstraZeneca PLC (AZN)'s Selumetinib Flunks Phase III Eye Cancer Study 7/22/2015
BioTie Therapies Corp. Announces Start Of Tozadenant Phase 3 Study In Parkinson's Disease 7/21/2015
Onxeo: Update On ReLive, Livatag International Phase III Clinical Trial In HCC 7/21/2015
Telesta Therapeutics Announces South Korean Partnership For MCNA & Concurrent Private Placement 7/20/2015
Pierre Fabre Release: Bladder Cancer Patients And Doctors Disappointed By Scottish Medicines Consortium's Negative Decision On Javlor (Vinflunine As Ditartrate) For The Treatment Of Adult Patients 7/13/2015
Regeneron (REGN), Sanofi (SAN.PA)'s Praluent Delivers in Late Stage Trial 7/9/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
AstraZeneca PLC (AZN) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China 7/8/2015
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015
RedHill Biopharma Ltd. (RDHL) Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104 7/6/2015
AEterna Zentaris (AEZS) Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer 6/30/2015
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy 6/25/2015
AEterna Zentaris (AEZS) Announces Selection Of ErgoMed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen In AGHD 6/25/2015
CSL Behring Presents rIX-FP For Hemophilia B Phase III Data Evaluating Efficacy, Safety And Improved Dosing At ISTH 2015 6/25/2015
Nuvo Research Inc. (NRI.TO) Provides Update On International Licensing Of Pennsaid 2% 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Novo Nordisk A/S (NVO) Release: In A Phase 3 Trial, Novoeight(Antihemophilic Factor [Recombinant]) Provided Long-Term Efficacy And Safety In The Prophylaxis And Treatment Of Bleeds In People With Hemophilia A 6/24/2015
Boehringer Ingelheim Phase III Pradax Anticoagulant Antidote Study Meets Primary Endpoints 6/22/2015
Resverlogix (RVX.TO) Officially Attains Phase 3 Status With A European Regulatory Authority 6/22/2015
MedDay Reports Additional Positive Data Of Its Pivotal Phase III Study With MD1003 In Patients With Progressive Multiple Sclerosis 6/19/2015
Eli Lilly (LLY) Release: CYRAMZA (ramucirumab) Hepatocellular Carcinoma Data Published By The Lancet Oncology 6/19/2015
RedHill Biopharma Ltd. (RDHL) Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease 6/16/2015
BioBlast Pharma (ORPN) Announces The Start Of A Phase III Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 6/15/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-2 Phase III Study For The Treatment Of Diabetic Foot Infection 6/15/2015
RedHill Biopharma Ltd. (RDHL) To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection 6/15/2015
RedHill Biopharma Ltd. (RDHL) Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection 6/15/2015
CTI BioPharma Release: Pacritinib Phase III Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis 6/12/2015
Genentech (RHHBY) Wins Breakthrough Nod From FDA for Systemic Sclerosis Treatment 6/11/2015
GW Pharma (GWPH) Initiates Second Phase III Pivotal Study Of Epidiolex (CBD) In Lennox-Gastaut Syndrome 6/11/2015
Alkermes (ALKS) Release: Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published In Journal Of Clinical Psychiatry 6/10/2015
Biogen (BIIB) And Samsung Bioepis Announce New Data For Three Anti-TNF Biosimilar Development Candidates At EULAR 2015 Congress 6/10/2015
Celgene (CELG) Release: Oral Presentation Evaluating Pooled Data On OTEZLA (Apremilast) For Long-Term Improvements In Enthesitis And Dactylitis To Be Presented At EULAR 6/10/2015
Merck & Co. (MRK) And Samsung Bioepis Announce Pivotal Phase III Studies For Investigational Biosimilars SB4, Enbrel (Etanercept), And SB2, Remicade (Infliximab), Met Primary Endpoints 6/10/2015
FDA Agrees With OncoGenex Pharmaceuticals Inc. (OGXI)' Phase 3 AFFINITY Protocol Amendment 6/10/2015
New Data Shows LEO Pharma A/S Investigational Psoriasis Treatment, Enstilar, Provides Rapid Itch Relief For Psoriasis Patients 6/10/2015
DalCor Pharma Licenses A Late-Stage Investigational Cardiovascular Drug Following Major Discovery By Montreal Heart Institute Scientists 6/8/2015
RedHill Biopharma Ltd. (RDHL) Completes Treatment Of Last Patient With RHB-105 In Phase III Study 6/8/2015
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA) 6/8/2015
AstraZeneca PLC (AZN)'s Booming Immuno-Onco Pipeline Validates Rebuffing Pfizer (PFE) 6/5/2015
ALK-Abello A/S Announces Top-Line Results From Its Partner Merck & Co. (MRK)'s North American Phase III Trial Of House Dust Mite SLIT-Tablet 6/4/2015
AstraZeneca PLC (AZN) Gets Closer to a Decision on Suicide-Linked Drug, CEO Says 6/3/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results 6/3/2015
Boehringer Ingelheim’s Vargatef (Nintedanib) In Combination With Docetaxel Is Recommended As A Treatment Option Within Its Marketing Authorisation For Patents With A Common Type Of Lung Cancer 6/2/2015
ASCO15: ERYtech Pharma Reported Full GRASPA Phase III Results In ALL And Provided Update On AML Phase IIb At ASCO 6/2/2015
NeuroVive: Neurovive Reports Topline Results Of Phase III CIRCUS Study In Acute Myocardial Infarction 6/1/2015
ASCO15: Boehringer Ingelheim Release: Superior Overall Survival For Afatinib Compared To Erlotinib Demonstrated In Head-To-Head Trial In Patients With Previously Treated Advanced Squamous Cell Carcinoma Of The Lung 6/1/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
BioTie Therapies Corp. Announces Agreement With FDA On A Special Protocol Assessment For Tozadenant Phase 3 Study 5/26/2015
Juventas Therapeutics, Inc. Presents New 12-Month Data Demonstrating Single Administration Of JVS-100 Improves Cardiac And Clinical Status In Patients With Severe Ischemic Heart Failure One Year After Treatment 5/26/2015
AEterna Zentaris (AEZS)' Confirmatory Phase 3 Study for Macrilen In AGHD Meets European Medicines Agency's Study-Design Expectations 5/26/2015
Cardiorentis Completes Enrollment In Pivotal Phase III Clinical Trial Of Ularitide For Acute Heart Failure 5/22/2015
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015
Debiopharm Announces Phase III Positive Results For Triptorelin 6-Month Formulation In The Management Of Central Precocious Puberty (CPP) 5/19/2015
RedHill Biopharma Ltd. (RDHL)'s Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market 5/18/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-1 Phase III Study For The Treatment Of Diabetic Foot Infection 5/15/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present Pivotal Data From Two Phase 3 Trials Demonstrating Safety And Efficacy Of Buprenorphine Hcl Buccal Film For The Management Of Chronic Pain 5/15/2015
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015
Chiasma Announces New Data For Investigational Octreotide Capsules To Be Presented At ECE 2015 5/11/2015
RedHill Biopharma Ltd. (RDHL) To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study 5/7/2015
ViiV Healthcare Begins Phase III Programme With dolutegravir/rilpivirine Combination For HIV Maintenance Therapy 5/6/2015
Indivior PLC Announces Positive Top-Line Results From Pivotal Phase 3 Trial Of RBP-7000 In Schizophrenia 5/5/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Improved Pharmacokinetic Profile In African-American Transplant Recipients 5/4/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015
AstraZeneca PLC (AZN) Release: Selumetinib Granted Orphan Drug Designation By FDA 4/29/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection 4/27/2015
Can-Fite BioPharma (CFBI) Reports Positive Results From Further Analysis Of Phase II/III Psoriasis Trial 4/27/2015
MedDay Reports Positive Pivotal Phase III Study Results With MD1003 In Patients With Progressive Multiple Sclerosis 4/24/2015
Janssen Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir Plus Sofosbuvir In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Janssen Sciences Ireland UC Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir ? Plus Sofosbuvir ? In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Medivir AB (MVRBF): Data From OPTIMIST Trials Show SVR12 Rates Of 97 Percent In HCV Patients Without Cirrhosis And 84 Percent In HCV Patients With Cirrhosis 4/23/2015
GW Pharmaceuticals (GWPH) Initiates Second Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 4/21/2015
Global Strategic Partners Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) nitiate Phase III Study With Avelumab* In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer 4/20/2015
Bio Products Laboratory, Ltd. Announces Results From Phase III Registration Study Of Its Factor X Coagulation Product 4/20/2015
Pembrolizumab, Merck & Co. (MRK)'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma 4/20/2015
MediWound (MDWD) Initiates U.S. Phase 3 Trial With NexoBrid To Treat Severe Burns 4/20/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015
MedDay Provides Update On Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis 4/7/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 4/1/2015
Pivotal Pharmacokinetic Study Of Innocoll, Inc. (INNL)'s Xaracoll(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain 4/1/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure(R) 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
OSE Pharma Collaboration For Cancer Trial 1/29/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Progress With RHB-104 Ongoing Phase 3 Program For Crohn's Disease Following FDA Meeting 1/29/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015



//-->